Acasă › Cancer de sân › Florida › Plantation
Studii clinice pentru Cancer de sân în Plantation, FL
14 studii pentru Cancer de sân caută participanți în și în jurul orașului Plantation (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
În curs de recrutareFaza 3
- Research Site, Plantation
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
În curs de recrutareFaza 3
- Miami Cancer Institute, Plantation
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
În curs de recrutareFaza 3
- Miami Cancer Institute at Plantation, Plantation
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
În curs de recrutareFaza 3
- University of Miami-SCCC-Plantation, Plantation
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
În curs de recrutareFaza 3
- Miami Cancer Institute at Plantation, Plantation
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
ATEMPT 2.0: Adjuvant T-DM1 vs TH
În curs de recrutareFaza 2
- Miami Cancer Institute - Plantation (MCIP), Plantation
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
În curs de recrutareFaza 3
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
În curs de recrutareFaza 3
- Miami Cancer Institute Plantation, Plantation
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
În curs de recrutareFaza 3
- BRCR Medical Center, Inc- Internal Medicine, Plantation
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
În curs de recrutareFaza 2
- Miami Cancer Institute at Baptist Health, Plantation
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
În curs de recrutareFaza 3
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
În curs de recrutareFaza 1
- BRCR Global, Plantation
- Florida Clinical Trials Group, Plantation
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- BRCR global, Plantation
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
În curs de recrutareStudiu observațional
- Baptist Cancer Care - Plantation, Plantation
Studii pentru Cancer de sân în alte orașe
- New York City, NY136 studii
- Houston, TX126 studii
- Boston, MA112 studii
- Nashville, TN81 studii
- Los Angeles, CA73 studii
- Edison, NJ68 studii
- St. Louis, MO64 studii
- Queens, NY64 studii
- Durham, NC64 studii
- Chicago, IL59 studii
- Philadelphia, PA56 studii
- Dallas, TX55 studii
Alte studii în Plantation
- Cancer pulmonar cu celule non-pătrate16 studii
- Cancer (toate tipurile)7 studii
- Lupus7 studii
- Cancer pulmonar7 studii
- Cancer metastatic6 studii
- Artrită reumatoidă6 studii
- Cancer de prostată5 studii
- Artrită psoriazică5 studii
- Cancer colorectal5 studii
- Melanom4 studii
- Mielom multiplu4 studii
- Cancer pulmonar cu celule mici4 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.